FOLH1 and prostate carcinoma: Interestingly, we did not directly observe variability in kidney uptake as a function of tumour burden which has been observed, for example, in prostate cancer patients treated with [177Lu]Lu-PSMA-167 or imaged with [68Ga]Ga-PSMA-11 [21, 22].